Activity of Brigatinib in Crizotinib and Ceritinib | 合法藥品大搜索

由 SM Lim 著作 · 2017 · 被引用 231 次 — Purpose ROS1 rearrangement is a distinct molecular subset of non-small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ... Read More

2017年8月8日 — Ceritinib could have indeed prevented the onset of the mutations of resistance in ROS1 TKD, known as conferring crizotinib exhaustion, delaying ... Read More

由 SM Lim 著作 · 2016 · 被引用 9 次 — Ceritinib demonstrated potent clinical activity in patients with advanced, ROS1-rearranged NSCLC, who received at least one prior line of platinum-based ... Read More

由 A Hegde 著作 · 2019 · 被引用 4 次 — Mechanisms of resistance to crizotinib in ROS1-positive NSCLC include mutations involving the ROS1 kinase domain and activation of bypass ... Read More

2017年5月18日 — ROS1 rearrangement is a therapeutically tractable oncogenic driver that occurs in 1% to 2% of patients with non–small-cell lung cancer (NSCLC). Read More

由 BC Cho 著作 · 2017 · 被引用 3 次 — Ceritinib in ROS1-Rearranged Non-. Small-Cell Lung Cancer: An Update of. Korean Nationwide Phase II Study. Byoung Chul Cho,1 Sun Min Lim,2 Hye Ryun Kim,3. Read More

Ceritinib 是第二代ALK 的TKI，大約比crizotinib 多20 倍效力。Ceritinib 已經被. FDA 核准用於ALK 呈現陽性的NSCLC 病人11。 ... ROS1 呈現陽性的非小細胞肺癌的轉. Read More

由 V Subbiah 著作 · 2016 · 被引用 31 次 — (1) on structural insight of ROS1 tyrosine kinase inhibitors. Non-small cell lung cancer (NSCLC) is no longer a single disease but a collection ... Read More

由 R NSCLC 著作 — Ceritinib Has Clinical Activity in Patients with ROS1-Rearranged NSCLC · Major finding: Ceritinib has manageable toxicity and achieves whole-body ... Read More

由 A D’Angelo 著作 · 2020 · 被引用 7 次 — Newer TKIs including repotrecninib, ceritinib, lorlatinib and entrectinib. Page 4. Cancers 2020, 12, 3293. 4 of 17 have been developed to ... Read More